Member Info for Greenfish89

:-)

I think we can influence the share price it just depends how many shares you have or how you influence people with a large amount of shares. Especially in these companies with a small number of available shares.

better luck with the next rns maybe?

I don't get home from work till half six i'll miss it :-(

Webinar Registration
Facebook Twitter LinkedIn Microsoft (Outlook)
Topic
COVID-19: Translating immune understanding and collaboration into new therapeutic strategies: Interferon beta story
Description
Ongoing development of treatments for COVID-19 requires a coordinated response across the UK's government bodies, clinical and academic research experts and the life sciences industry. The NIHR - Respiratory Translational Research Collaboration (R TRC) has played a significant role in coordinating the phase 2 clinical trials for new drugs during the COVID-19 pandemic.

In this webinar, Dr Alex Horsley, the co-chair for the NIHR Respiratory TRC will describe UK’s response in this space while Prof Jan Rehwinkel from University of Oxford will talk about the latest understanding of how type I IFN detect and control SARS-CoV2 virus. Finally, Prof Tom Wilkinson, the Chief Investigator for Synairgen's phase 2 trial for nebulised type I IFN will discuss the results.

Presentations will be followed by a Q&A session.

Agenda:
16.30 - 16.35
Welcome and introduction, Prof Ling-Pei Ho, University of Oxford, R TRC Chair

16:35 - 16.50
Responding to the challenge: the evolving landscape of COVID-19 phase 2 trials in UK, Dr Alex Horsley, University of Manchester, R TRC Deputy Chair

1650 - 17.15
Type I IFN – detection and control of SARS-CoV2, Prof Jan Rehwinkel, University of Oxford

17.15- 17.45
Safety and efficacy of inhaled nebulised interferon beta-1a SARS-CoV-2 infection: a randomised, double-blind, placebo controlled Phase 2 trial, Prof Tom Wilkinson, University of Southampton, SNG001 trial Chief Investigator

17.45 - 18.00
Q&A session moderated by Prof Ling-Pei Ho

18.00 - Close
Time

Nov 30, 2020 04:30 PM in London
https://ccf-nihr.zoom.us/webinar/register/WN_KZLwXfmUQaS3Cu0-UU48Zw

two options because people have sold their shares or market makers making a market.
In the short term it means we don't get as much if we sell and if the company needed money it would cause more dilution then if the shares were higher.
it means nothing about the product or the likelyhood of a use for it.
it might mean the company sells cheaper than they would if we were at a high share price but thats down to the managment at the end of the day.
Roll on phase 3 results

Show me the money !!!

I thought we would be scooping sand off the beach and making money by now :-( still the JV is good news.

it depends what it does to the ones who get it first

Yes it's the market cap that matters not the share price. But if you have more shares the percentage rise will be less to get to the value the market believes the company is worth as the market cap I just the number of shares X the share price.

a bird in the hand is worth two in the bush. it may go the way everyone wants but it could crash and burn next week you can never tell with aim. i'd sell it and enjoy the house. There will be another share.

I think your wrong depending on how much money is involved not only do you get posters who as a group try to move a share price but also you get false news stories also. They won't get paid a wage maybe but they will get renumerated.

It depends how good the vacine is. If the virus changes too often for a vaccine to be effective. Also if people will take the vaccine. At the moment it's only NHS and vunrable who get it. If it comes out this year.
Fingers crossed sng get going sharp ish.
Even if covid is sorted sng will be ready for the next big thing. And copd

Show me the money

Stop being so wet and people won't "bully you"

Fraser give it a rest.

The market makers just bleed you dry

Omi, sng,jay

There is no joint venture in ufo! They just need money I don't understand their rise.

https://www.ft.com/content/ee9b611f-2b4b-4572-afe1-b0b804d17a94